CD19 and B-cell acute lymphoblastic leukemia: For example, in clinical trials, CAR-T cells targeting EGFR and CD133 together prolonged the survival time of patients with advanced cholangiocarcinoma [51], and the combination of anti-CD19 and anti-CD20 CAR-T cells also improved the survival time of patients with relapsed B cell acute lymphoblastic leukemia [52].